Molika Ashford

Company investigators calculated the expected reduction in late-stage cancer diagnoses and projected drops in mortality for different screening schedules in different models of cancer growth.

The company continues to see increased adoption of its Decipher and Afirma tests, and said it is making changes to its IVD manufacturing business.

The company beat Wall Street expectations on the top and bottom lines, attributing its growth to both clinical and pharma adoption of its residual cancer testing platform.

At the AACR annual meeting, investigators presented promising data across genomic and protein-based technologies, highlighting synergies that could improve performance.

The firm presented a slew of new data at the AACR annual meeting this week on its core therapy selection tests, its MRD assay, and its early cancer detection test.

Investigators reported on the firm's ctDNA residual disease assay to detect disease in colorectal patients during the ideal window for guiding therapy.

The company said clinical revenue drove growth and raised its full-year 2025 guidance to reflect added income from its recent acquisition of clinical lab Pathline.

The company's data is still preliminary, but it believes its approach could help reduce unnecessary prostate biopsies and aid in cancer monitoring and screening.

The company has been offering the test on a limited basis but now plans to market it more broadly after a large validation study showed high sensitivity and specificity.

The firm believes its platform, which uses a swallowable capsule sample collection device, can improve the identification and care of patients with esophageal pre-cancer.